Abstract
γ-Secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimers disease (AD). This novel concept of manipulating the cleavage specificity of the γ-secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-β(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease. Following on from the initial discovery that certain non-steroidal anti-inflammatory drugs (NSAIDs) exhibit properties characteristic of γ-secretase modulators, this class of compounds has been extensively studied and exploited, leading to the discovery of NSAIDs derivatives endowed with improved potency for the reduction of amyloid-β(1-42) peptide production. In addition, a very limited number of non-NSAID derived γ-secretase modulators has also been recently claimed in the patent literature, suggesting that only a restricted number of pharmacophores might be involved in the modulation of γ-secretase.
Current Topics in Medicinal Chemistry
Title: γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective
Volume: 8 Issue: 1
Author(s): Ilaria Peretto and Elena La Porta
Affiliation:
Abstract: γ-Secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimers disease (AD). This novel concept of manipulating the cleavage specificity of the γ-secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-β(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease. Following on from the initial discovery that certain non-steroidal anti-inflammatory drugs (NSAIDs) exhibit properties characteristic of γ-secretase modulators, this class of compounds has been extensively studied and exploited, leading to the discovery of NSAIDs derivatives endowed with improved potency for the reduction of amyloid-β(1-42) peptide production. In addition, a very limited number of non-NSAID derived γ-secretase modulators has also been recently claimed in the patent literature, suggesting that only a restricted number of pharmacophores might be involved in the modulation of γ-secretase.
Export Options
About this article
Cite this article as:
Peretto Ilaria and Porta La Elena, γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334097
DOI https://dx.doi.org/10.2174/156802608783334097 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Exploring the Nucleolar Proteome: Novel Concepts for Chaperone Trafficking and Function
Current Proteomics Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Clinical Aspects of Tumor Necrosis Factor-α Signaling in Hepatocellular Carcinoma
Current Pharmaceutical Design Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Dopamine and the Diseased Brain
CNS & Neurological Disorders - Drug Targets Induction of SIV p27-Specific Multifunctional T Cells in the Gut Following Prime-Boost Immunization with Clostridium perfringens and Adenovirus Vaccines Expressing SIV p27
Current HIV Research Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry The Role of Melatonin in Rheumatic Diseases
Infectious Disorders - Drug Targets New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Assessment of Antioxidant Capacity of Natural Products
Current Pharmaceutical Biotechnology Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design In vitro Effects of Polyphenols on the Peripheral Immune Responses in Nickel-sensitized Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets The Bioartificial Kidney in the Treatment of Acute Kidney Injury
Current Drug Targets Psychological Stress and Puerperal Mastitis - Possible Pathophysiological Mechanisms
Current Women`s Health Reviews